Know Cancer

forgot password

A Pilot Multivalent Conjugate Vaccine Trial for Patients With Biochemically Relapsed Prostate Cancer

Phase 2
18 Years
Not Enrolling
Prostate, Cancer

Thank you

Trial Information

A Pilot Multivalent Conjugate Vaccine Trial for Patients With Biochemically Relapsed Prostate Cancer

This is a pilot trial designed to assess safety and immunogenicity of a multivalent
conjugate vaccine for use in patients with biochemically relapsed prostate cancer. This
trial is based on the results of eight dose-seeking phase I monovalent glycoprotein and
carbohydrate conjugate vaccine trials in a patient population with minimal tumor burden
despite a rising biomarker, PSA, who have failed primary therapy such as surgery or
radiation. We know that a rising PSA is indicative of micrometastatic disease - a state to
which the immune system may maximally respond. Based on these trials, we have identified
three glycolipid antigens, Globo H, Lewisy and GM2 and three mucin antigens, glycosylated
MUC-1, Tn(c), and TF(c) for inclusion into a multivalent trial. As a result of these
vaccinations, most patients generated specific high titer IgM and IgG antibodies against the
respective antigen-KLH conjugates. Our previous work has shown the monovalent vaccines to
be safe with local erythema and edema but minimal systemic toxicities. Our data from
approximately 160 men who participated in our earlier monovalent vaccine trials against the
aforementioned antigens have shown that a treatment effect in the form of a decline in PSA
log slopes compared with pretreatment values could be seen in patients with minimal tumor
burden. The multivalent vaccine will consist of the lowest dose of synthetic glycoprotein
and carbohydrate antigens shown to elicit high titer IgM and IgG antibodies in patients with
biochemically relapsed prostate cancer. A phase III double blind randomized trial with two
hundred forty patients is planned based on the safety and immunogenicity data accrued from
this pilot trial.

The primary endpoints of this study will be the safety of the vaccine and the humoral
response to each of the antigens. The secondary endpoint will be to evaluate post-therapy
changes in PSA.

Inclusion Criteria:

- Patients with prostate cancer that is histologically confirmed.

- Patients must show biochemical progression after primary therapy, including surgery
or radiation (with or without neo-adjuvant androgen ablation). This detection of PSA
following treatment must occur within two years.

- Patients who have had intermittent hormonal treatment, following primary therapy, who
have non-castrate levels of testosterone (>50 ng/ml) are eligible. Hormonal status
will be recorded on the basis of serum testosterone levels.

- Karnofsky performance status >60%.

- Patients must have adequate organ function as defined by:

1. WBC > or = to 3500/mm3, platelet count > or = to 100,000 mm3.

2. Bilirubin <2.0 mg/100 ml or SGOT <3.0 X's the upper limit of normal.

3. Creatinine < or = to 2.0 mg/100 ml or creatinine clearance > or = to 40 cc/min.

- Patients must have recovered from the toxicity of any prior therapy, and not received
chemotherapy or radiation therapy for at least 4 weeks prior to entry into the trial.

- No history of an active secondary malignancy within the prior five years except for
nonmelanoma skin cancer. Patients with history of melanoma in situ will be permitted
since these lesions behave in a manner similar to compound nevi.

- Patients must be at least 18 years of age.

- Patients must sign informed consent.

Exclusion Criteria:

- Clinically significant cardiac disease (New York Heart Association Class III/IV), or
severe debilitating pulmonary disease.

- Radiographic evidence of metastatic disease.

- An infection requiring antibiotic treatment.

- Narcotic dependent pain.

- Anticipated survival of less than 6 months.

- Positive stool guaiac excluding hemorrhoids or history of documented radiation
induced proctitis.

- Allergy to seafood.

- Prior vaccine therapy at outside institution except for phase I monovalent trial
performed at MSKCC.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall antitumor assessment performed during weeks 19 and 31. If no progression of disease continue on protocol. After week 31, will be monitored every 3 months with history, physical, performance status and bloodwork. Imaging studies every 6 mo.

Outcome Time Frame:


Safety Issue:


Principal Investigator

Susan Slovin, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

November 2000

Completion Date:

March 2009

Related Keywords:

  • Prostate
  • Cancer
  • prostate
  • cancer
  • vaccine
  • Prostatic Neoplasms



Memorial Sloan-Kettering Cancer CenterNew York, New York  10021